Emergency Use Authorization (EUA) is a regulatory mechanism to allow the use of vaccines and medicines to prevent and/or reduce the impact of life- threatening diseases or conditions as caused by COVID-19.
An Emergency Use Authorization in the United States is an authorization granted to the Food and Drug Administration under sections of the Federal Food, Drug, and Cosmetic Act.
The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies.
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), when the Secretary of HHS declares that an emergency use authorization is appropriate, FDA may authorize unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases.
Examples of EUA in Recent History:
The EUA mechanism has been crucial in addressing several major public health crises, particularly in the rapid deployment of innovative medical solutions.
- COVID-19 Vaccines & Therapeutics: mRNA vaccines such as Pfizer-BioNTech and Moderna, along with antiviral treatments like Remdesivir, received EUA to help combat the pandemic.
- Diagnostic Tests: Numerous rapid antigen and PCR tests for COVID-19 were granted EUA, enabling widespread and timely detection of infections.
- Antivirals & Monoclonal Antibodies: Specific antiviral drugs and monoclonal antibody treatments received EUA to provide targeted therapies against viral threats.
Criteria for Issuance of EUA:
The FDA applies rigorous criteria to ensure that only justified medical products receive Emergency
Use Authorization.
- Serious Condition – The disease or condition must be serious or life-threatening, posing a significant public health risk.
- Evidence of Effectiveness: Sufficient evidence of effectiveness must be present, based on the best available scientific data at the time of authorization.
- Benefits Outweigh Risks: The known and potential benefits must outweigh the known and potential risks in the emergency context.
- No Alternatives: There should be no adequate, approved, and available alternatives for the product’s intended use.
Risks and Limitations:
- Limited Data: Products authorized under EUA often have less extensive clinical data compared to those that undergo full FDA approval.
- Unknown Adverse Effects: The expedited review process may result in rare or long-term adverse effects not being fully identified until after widespread use.
- Revocation Potential: An EUA can be revoked or terminated if new data challenge the benefit-risk assessment or if fully approved alternatives become available.
Benefits of EUA:
- Accelerated Availability – EUA significantly shortens the time required to make critical medicines and diagnostics accessible during acute emergencies.
- Public Health Preparedness – Acts as a crucial tool for enabling a nation to respond swiftly and effectively to unforeseen health crises.
- Flexible Regulatory Approach – Offers a flexible regulatory pathway that adapts to evolving scientific understanding while maintaining safety standards.
FAQS
Q.1 What is the difference between compassionate use and emergency use authorization?
IRB agreement that a particular case meets FDA criteria for emergency use applies to the treatment of one patient only and is not the same as IRB approval to conduct a research study. Expanded access, sometimes called “compassionate use,” is the use outside of a clinical trial of an investigational medical product.
Q.2 What is the emergency use consent?
For emergency use of a drug, biologic or device, the investigator is required to obtain the written informed consent of the participant or the participant’s legally authorized representative. Investigators may use the IRB’s Emergency Use Consent template.
Q.3 What are the three types of emergency provisions in India?
Three types of emergencies are addressed in the Constitution of India: Nation Emergency, State Emergency, and Financial Emergency. Article 352 of Part XVIII of the Constitution includes the national emergencies, Article 356 enlists the state emergencies, and Article 360 incorporates the financial emergencies.
Q.4 What is the emergency use authorization for vaccines?
Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate and approved.
Q.5 What are the importance of EUA in India?
- Rapid Access: Speeds up availability of vaccines, medicines, and diagnostics during health crises.
- Public Health Response: Enables swift action to control outbreaks and reduce mortality.
- Boost to Local Manufacturing: Encourages domestic production and innovation in pharma and biotech.
- Regulatory Flexibility: Allows DCGI to approve products based on interim safety and efficacy data.
- Global Collaboration: Aligns India’s emergency health measures with international standards and initiatives.
